Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Doubek

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 8, 2024
Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months…A Čermák, J Foukal, Z Řehák, et al.
Bone Marrow Transplantation|October 27, 2009
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALLS Giebel, B Stella-Holowiecka, M Krawczyk-Kulis, et al.
Leukemia|October 8, 2014
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemiaJ Malcikova, K Stano-Kozubik, B Tichy, et al.
Vnitrni Lekarstvi|September 11, 2008
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]M Penka, J Schwarz, T Pavlík, et al.
Oncology|April 28, 2012
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experienceD Zapletalova, N André, L Deak, et al.
Leukemia|July 27, 2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational statusB Kubesova, S Pavlova, J Malcikova, et al.
Vnitrni Lekarstvi|December 19, 2009
[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin]M Penka, J Schwarz, T Pavlík, et al.
Vnitrni Lekarstvi|June 15, 2006
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]M Penka, M Doubek, J Schwarz, et al.
Blood Cancer Journal|September 24, 2016
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaN Gökbuget, M Kelsh, V Chia, et al.
Vnitrni Lekarstvi|August 19, 2007
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006]M Penka, J Schwarz, T Pavlík, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 8, 2024
Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months…A Čermák, J Foukal, Z Řehák, et al.
Bone Marrow Transplantation|October 27, 2009
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALLS Giebel, B Stella-Holowiecka, M Krawczyk-Kulis, et al.
Leukemia|October 8, 2014
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemiaJ Malcikova, K Stano-Kozubik, B Tichy, et al.
Vnitrni Lekarstvi|September 11, 2008
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]M Penka, J Schwarz, T Pavlík, et al.
Oncology|April 28, 2012
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experienceD Zapletalova, N André, L Deak, et al.
Leukemia|July 27, 2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational statusB Kubesova, S Pavlova, J Malcikova, et al.
Vnitrni Lekarstvi|December 19, 2009
[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin]M Penka, J Schwarz, T Pavlík, et al.
Vnitrni Lekarstvi|June 15, 2006
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]M Penka, M Doubek, J Schwarz, et al.
Blood Cancer Journal|September 24, 2016
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaN Gökbuget, M Kelsh, V Chia, et al.
Vnitrni Lekarstvi|August 19, 2007
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006]M Penka, J Schwarz, T Pavlík, et al.
Pageof 7